What is GALT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.40B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GALT?

P/E (TTM) is n/a and 52-week range is $2.02 to $7.13 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GALT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GALT?

The company profile lists net income (TTM) near $-28M, EPS (TTM) near $-0.43 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Galectin Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Norcross, Georgia, US, 65.9M shares outstanding, ISIN US3632252025 when available from company profile and filing metadata.

Galectin Therapeutics Inc

$GALT

Health Care · Biotechnology

IR Run Scenarios

$3.94

+8.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 9 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Employees

Website

galectintherapeutics.com/

IPO

2002-09-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)